ViiV Healthcare is a global specialist HIV company dedicated to delivering advances in treatment and care for people living with HIV. We are an independent pharmaceutical company established in 2009 by combining the power and expertise in the management of HIV from both GlaxoSmithKline (GSK) and Pfizer. Following a long-term collaboration on the joint development of several novel integrase inhibitors we were joined by Shionogi  in 2012. Our current portfolio of eleven HIV treatments generated annual sales of £1.4 billion in 2012 providing us with the financial stability to take a sustainable, long-term view when investing in our pipeline of new medicines. Our scientists are 100% dedicated to finding new ways to limit the impact of HIV on the 34 million people living with the virus and understanding how best to prevent and treat the disease.